Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL

Exclusion Criteria

• •1. Used immunosuppressive agents or therapeutic doses of corticosteroids (defined as prednisone\>20mg or equivalent dose) within one week before blood collection, or used drugs that stimulate bone marrow hematopoiesis, such as Human Granulocyte Colony Stimulating Factor (G-CSF); But physiological substitution, topical or inhaled steroids are permitted;
• •2. Uncontrolled systemic active fungi, bacteria, viruses or other infections;
• •3. Active hepatitis B (HBV DNA\>500IU/mL), hepatitis C (HCV RNA positive) or human immunodeficiency virus (HIV) antibody positive;
• •4. Central nervous system invasion, or central nervous system disease history, such as epilepsy, cerebrovascular disease, etc;
• •5. Pregnant or lactating women, or patients do not agree to use effective contraceptives during treatment and within the following 1 year;
• •6. Receiving allogeneic hematopoietic stem cell transplantation or organ transplantation;
• •7. Previous history of other malignant tumors. Patients with cured skin basal or squamous cell carcinoma and cervical carcinoma in situ at any time before the study were not included; Patients with other tumors not listed above, but which have been cured by surgery but not by other further treatment measures, and disease-free survival≥5 years, can be included in the study;
• •8. Patients with primary immunodeficiency or autoimmune diseases, but asymptomatic hypothyroidism, or well controlled type I diabetes can participate in this study;
• •9. Patients who participated in other clinical trials within 4 weeks before blood collection;
• •10. The investigator considers that there are other factors that are not suitable for inclusion or affect the subjects to participate in or complete the study.